Guggenheim Maintains Buy on Insmed, Lowers Price Target to $226

Benzinga Newsdesk www.benzinga.com Negative 77.5%

Neg 77.5% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $230 to $226.

Comments

No comments yet. Be the first!